Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Swanton

Showing results (41-50 of 439) with videos related to

Pageof 44
Sort By:
The Lancet. Oncology|March 26, 2011
KRAS 3'-UTR variants and stratification of breast-cancer riskMadhu S Kumar, Charles Swanton
BMC Medicine|July 19, 2017
The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcomeDeborah R Caswell, Charles Swanton
The Lancet. Oncology|July 20, 2014
Combined inhibition of BRAF and MEK in melanoma patientsJeffrey R Infante, Charles Swanton
Molecular Oncology|August 5, 2014
Tumour heterogeneity and the evolution of polyclonal drug resistanceRebecca A Burrell, Charles Swanton
Cancer Biology & Therapy|October 10, 2009
Advances in personalized therapeutics in non-small cell lung cancer: 4q12 amplification, PDGFRA oncogene addiction and sunitinib sensitivityCharles Swanton, Rebecca A Burrell
Cancer Discovery|August 3, 2017
The GENIE Is Out of the Bottle: Landmark Cancer Genomics Dataset ReleasedKevin Litchfield, Samra Turajlic, Charles Swanton
The Lancet. Oncology|November 4, 2004
RNA interference, DNA methylation, and gene silencing: a bright future for cancer therapy?Charles Swanton, Barbara Nicke, Julian Downward
Frontiers in Oncology|June 2, 2012
Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma?Rosalie Fisher, James Larkin, Charles Swanton
The New England Journal of Medicine|July 9, 2025
Tumor-Infiltrating Clonal Hematopoiesis. ReplyElsa Bernard, Oriol Pich, Charles Swanton
Cell Cycle (Georgetown, Tex.)|April 22, 2006
Chromosomal instability, colorectal cancer and taxane resistanceCharles Swanton, Ian Tomlinson, Julian Downward
Pageof 44

Showing results (41-50 of 439) with videos related to

Sort By:
Pageof 44
The Lancet. Oncology|March 26, 2011
KRAS 3'-UTR variants and stratification of breast-cancer riskMadhu S Kumar, Charles Swanton
BMC Medicine|July 19, 2017
The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcomeDeborah R Caswell, Charles Swanton
The Lancet. Oncology|July 20, 2014
Combined inhibition of BRAF and MEK in melanoma patientsJeffrey R Infante, Charles Swanton
Molecular Oncology|August 5, 2014
Tumour heterogeneity and the evolution of polyclonal drug resistanceRebecca A Burrell, Charles Swanton
Cancer Biology & Therapy|October 10, 2009
Advances in personalized therapeutics in non-small cell lung cancer: 4q12 amplification, PDGFRA oncogene addiction and sunitinib sensitivityCharles Swanton, Rebecca A Burrell
Cancer Discovery|August 3, 2017
The GENIE Is Out of the Bottle: Landmark Cancer Genomics Dataset ReleasedKevin Litchfield, Samra Turajlic, Charles Swanton
The Lancet. Oncology|November 4, 2004
RNA interference, DNA methylation, and gene silencing: a bright future for cancer therapy?Charles Swanton, Barbara Nicke, Julian Downward
Frontiers in Oncology|June 2, 2012
Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma?Rosalie Fisher, James Larkin, Charles Swanton
The New England Journal of Medicine|July 9, 2025
Tumor-Infiltrating Clonal Hematopoiesis. ReplyElsa Bernard, Oriol Pich, Charles Swanton
Cell Cycle (Georgetown, Tex.)|April 22, 2006
Chromosomal instability, colorectal cancer and taxane resistanceCharles Swanton, Ian Tomlinson, Julian Downward
Pageof 44